Overview

Principal Investigator

Massimo Gadina, Ph.D.

Dr. Gadina is exploring immune-mediated diseases with a particular emphasis on the biology of cytokines, their relative signaling pathways and has an keen interest in the role of JAK inhibitors in the treatment of inflammatory and autoimmune diseases.

The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting-edge immune monitoring technology that will be made available to all NIAMS investigators.

The Translational Immunology Section supports NIAMS scientists with:

  • Consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
  • State-of-the-art immunoassays such as high parameters, multicolor flow cytometry, Luminex, and NanoString transcriptomic analysis enabling NIAMS clinicians to monitor the immune responses of their patients.
  • Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.
  • Analysis of the mechanism of action of JAK inhibitors on various immune cell populations.

Contact Us

Ronnie Gladney

Administrative Assistant
10 Center Drive
Building 10, Room 10N311
Bethesda MD 20892

Scientific Publications

Selected Recent Publications

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, Shea JJO, Gadina M, Kaplan MJ
Nat Commun.
2021 Jun 7;
12(1).
doi: 10.1038/s41467-021-23361-z
PMID: 34099646

JAK1: Number one in the family; number one in inflammation?

Spinelli FR, Colbert RA, Gadina M
Rheumatology (Oxford).
2021 May 5;
60(Supplement_2).
doi: 10.1093/rheumatology/keab024
PMID: 33950229

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
Ann Rheum Dis.
2020 Aug 25;
pii: annrheumdis-2020-218690. doi: 10.1136/annrheumdis-2020-218690
PMID: 32843325

Translating JAKs to Jakinibs.

Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O'Shea JJ
J Immunol.
2020 Apr 15;
204(8).
doi: 10.4049/jimmunol.1901477
PMID: 32253269

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.

Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, Liu L, Stoffels M, Kratina T, Lawlor KE, Zaal KJM, Hoffmann PM, Etemadi N, Shield-Artin K, Biben C, Tsai WL, Blake MD, Kuehn HS, Yang D, Anderton H, Silke N, Wachsmuth L, Zheng L, Moura NS, Beck DB, Gutierrez-Cruz G, Ombrello AK, Pinto-Patarroyo GP, Kueh AJ, Herold MJ, Hall C, Wang H, Chae JJ, Dmitrieva NI, McKenzie M, Light A, Barham BK, Jones A, Romeo TM, Zhou Q, Aksentijevich I, Mullikin JC, Gross AJ, Shum AK, Hawkins ED, Masters SL, Lenardo MJ, Boehm M, Rosenzweig SD, Pasparakis M, Voss AK, Gadina M, Kastner DL, Silke J
Nature.
2020 Jan;
577(7788).
doi: 10.1038/s41586-019-1828-5
PMID: 31827281

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

Simon N, Antignani A, Hewitt SM, Gadina M, Alewine C, FitzGerald D
JCI Insight.
2019 Mar 7;
4(5).
pii: 123281. doi: 10.1172/jci.insight.123281
PMID: 30720466

Selective Janus kinase inhibitors come of age.

O'Shea JJ, Gadina M
Nat Rev Rheumatol.
2019 Feb;
15(2).
doi: 10.1038/s41584-018-0155-9
PMID: 30622297

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R
J Clin Invest.
2018 Jul 2;
128(7).
doi: 10.1172/JCI98814
PMID: 29649002

Key Publications

JAK inhibitors: Ten years after.

Spinelli FR, Meylan F, O'Shea JJ, Gadina M
Eur J Immunol.
2021 Apr 30;
doi: 10.1002/eji.202048922
PMID: 33930196

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC
N Engl J Med.
2020 Dec 31;
383(27).
doi: 10.1056/NEJMoa2026834
PMID: 33108101

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.

Spinelli FR, Conti F, Gadina M
Sci Immunol.
2020 May 8;
5(47).
pii: eabc5367. doi: 10.1126/sciimmunol.abc5367
PMID: 32385052

JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.

Vian L, Le MT, Gazaniga N, Kieltyka J, Liu C, Pietropaolo G, Dell'Orso S, Brooks SR, Furumoto Y, Thomas CJ, O'Shea JJ, Sciumè G, Gadina M
Front Immunol.
2019;
10().
doi: 10.3389/fimmu.2019.02972
PMID: 31921209

High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.

Tsai WL, Vian L, Giudice V, Kieltyka J, Liu C, Fonseca V, Gazaniga N, Gao S, Kajigaya S, Young NS, Biancotto A, Gadina M
J Immunol Methods.
2020 Feb;
477().
doi: 10.1016/j.jim.2019.112667
PMID: 31726053

News & Highlights

Research Brief | January 9, 2017

Tofacitinib Shows Potential for Treating Lupus

A drug that effectively treats rheumatoid arthritis (RA) and can improve symptoms in other autoimmune diseases may also control the symptoms associated with systemic lupus erythematosus (SLE or lupus) and potentially slow the disease’s progression.
EmailPrintShare
Last Updated: June 2021 Back to Top